Endovascular Therapy for Posterior Circulation Stroke After 1 Day

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized trial compares endovascular therapy plus standard care to standard care alone in adults with basilar or vertebral artery occlusion occurring more than 24 hours after onset. It uses an open-label design with blinded outcome assessment and aims to enroll 244 participants across centers in China. The primary outcome is the proportion achieving a 90-day mRS of 0-3, with secondary outcomes including full 90-day mRS distribution and quality-of-life measures. Follow-up lasts 90 days, with overall study duration planned at 36 months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old
2. Baseline NIHSS score of 4 or higher, maintained prior to randomization
3. Stroke onset or more than 24 hours since the last known good state, but within 14 days
4. CTA/MRA/DSA confirmed occlusion of the responsible vessel in basilar artery or intracranial segments of both vertebral arteries (V4)
5. Modified Rankin Scale (mRS) score of 0 or 1 pre-stroke
6. The subject or their legally authorized representative has signed the informed consent form for the study

Exclusion Criteria:

1. Hemorrhage on CT or MRI
2. Based on the judgment of the treating physician, the patient is considered unlikely to benefit from the trial (e.g., advanced dementia, severe pre-stroke disability (mRS ≥ 2), or high risk of early mortality)
3. Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.).
4. Evidence of vascular recanalization prior to randomization
5. Uncontrolled seizures at the time of stroke onset, if they interfere with obtaining an accurate baseline NIHSS
6. Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \< 6 on non-contrast CT or CT angiography source images or MR with diffusion-weighted imaging
7. Complete cerebellar infarct with significant mass effect and compression of the fourth ventricle,or bilateral thalamic infarction on CT or MRI
8. Baseline platelet count \<50,000/uL
9. Severe, persistent hypertension (systolic blood pressure \> 220 mmHg or diastolic blood pressure \> 120 mmHg)
10. Known hereditary or acquired bleeding disorders, coagulation factor deficiencies, or recent oral anticoagulant therapy with an International Normalized Ratio (INR) \> 3
11. Suspected purulent embolism, with a suspicion of bacterial endocarditis
12. Known allergies to iodine, heparin, anesthetics, or other explicit contraindications to the endovascular treatment procedure
13. Pregnancy
14. Other serious, progressive, or end-stage diseases (as determined by the investigator) or a life expectancy of less than 6 months
15. Attempted use of a neurothrombectomy device to remove the clot prior to randomization
16. Currently participating in a study involving other investigational drugs or devices
17. Evidence of intracranial tumor on CT or MRI (excluding meningioma)
18. CTA/MRA showing excessive tortuosity of the cervical vessels, which may interfere with endovascular treatment
19. Suspicion of aortic dissection based on medical history and CTA/MRA findings
20. Any other conditions that the investigator believes may interfere with the endovascular procedure or pose significant risk to the subject during the procedure

Where it's running

• Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Bo Hu, Doctor
• Email: hubo@mail.hust.edu.cn
• Phone: 13707114863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• Pulse Wave vs Saline Bolus EIT to measure lung perfusion in ARDS

  This study tests whether pulse wave EIT or saline bolus EIT can best show lung blood flow in ARDS patients on mechanical ventilation.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07908368

• AI-powered CT help to guide pneumonia care

  A multicenter trial tests whether using a chest CT–based AI report to guide care reduces death or need for new organ support in adults with pneumonia.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895290

• AI-assisted longitudinal CT to guide indeterminate lung nodules

  This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895277

• Low-Dose CBCT AI Model for Interventions

  This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.

  Recruiting at 5 sites Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hefei, Anhui and 4 other locations · NCT07845929

• Dalpiciclib with an aromatase inhibitor and olmesartan as first-line therapy for HR+/HER2- advanced breast cancer

  This trial tests whether adding dalpiciclib and olmesartan to an aromatase inhibitor helps people with HR+/HER2- advanced breast cancer respond to first-line treatment.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07810088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.